DPP-4 inhibitors may have specific autoimmune risks
MDSpire News
September 24, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise:
4 Topic Commentaries
DPP-4 inhibitors may have specific autoimmune risks
Dae Hyun Kim, MD, MPH, ScD
Geriatrics; Pharmacoepidemiology
•Beth Israel Deaconess Medical Center and Harvard Medical School
Hemin Lee, MD, MPH
Pharmacoepidemiology; Internal Medicine
•Brigham and Women’s Hospital, Harvard Medical School
Reuven Bergman, MD
Dermatology
•Technion—Israel Institute of Technology; Department of Dermatology, Rambam Health Care Campus
Devin Abrahami, Not specified
Pharmacoepidemiology
•McGill University
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.